Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.53 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.60 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076926 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL11064695 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL10795479 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL28478794 | 0.79 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL8369049 | 0.79 | CHRNA1 (0.43) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL24467444 | 0.78 | CHRNA1 (0.52) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL10480710 | 0.76 | CYP2D6 (0.46) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL1974393 | 0.76 | HTR1D (0.52) | SIGMAR1GAAGFERCYP1A2CYP2D6 | |
| Desnitroimidacloprid SCHEMBL29823081 | 0.76 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL4102420 | 0.75 | HTR1D (0.55) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919921-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7494984-B2 | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1919921-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027754-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | CCNI, APOBEC3C, CDKN1A | SIGMAR1 3960/4885HTR1D 2854/4885HTR1B 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.